psoriasis News
Most Popular psoriasis Story
Pfizer's tasocitinib for psoriasis shows Phase II promise
Pfizer is touting results from a Phase II trial of tasocitinib (CP-690,550), an oral JAK inhibitor for moderate to severe plaque psoriasis. The drug is designed to block enzymes that play a key role Read more...
Latest Headlines
- October 4, 2011
- October 7, 2010
- September 18, 2008
- June 13, 2008
- June 5, 2008
- February 5, 2008
- October 23, 2007
- October 4, 2007
- September 26, 2007
- September 24, 2007
- January 3, 2007
- June 28, 2006
- June 15, 2006
- June 7, 2006
- March 19, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
